The Cancer Genome Atlas Validation of Ancillary Tests for Classifying Papillary Thyroid Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: Ancillary tests such as BRAFV600E mutation or immunohistochemical (IHC) assays have been utilized as complements to morphological criteria in diagnosing subsets of papillary thyroid carcinoma (PTC). Utilizing results from analysis by The Cancer Genome Atlas (TCGA), we evaluated the diagnostic value and feasibility of these ancillary tests in diagnosing follicular variant PTC (FVPTC). Materials and Methods: Clinical data and tissue samples were analyzed from 370 PTC patients, who had undergone thyroidectomy between December 2003 and July 2014. PTC was limited to conventional PTC (CVPTC), tall cell variant PTC (TCPTC), and FVPTC. Using multivariate analyses, FVPTC cases were compared to CVPTC and TCPTC cases. Surgical specimens were pyrosequenced for BRAFV600E mutation or stained for IHC markers such as CD56, galectin-3, cytokeratin 19 (CK19), or CD31. For the validation, a comprehensive analysis was performed for BRAFV600E mutation and quantitative mRNA expressional difference in TCGA. Results: Demographic differences were not observed between 159 CVPTC, 103 TCPTC, and 108 FVPTC cases. BRAFV600E mutation predominated in CVPTC＋TCPTC group, but not in FVPTC group (78.4% vs. 18.7%, p＜0.001), as suggested by TCGA (57.4% vs. 12.1%, p＜0.0001). IHC markers significantly distinguished FVPTC cases from CVPTC＋TCPTC cases. CD56 exhibited more intense staining in FVPTC cases (21.1% vs. 72.0%, p＜0.001). Galectin-3 and CK19 yielded limited values. CD31 correlated with lymphovascular invasion (r=0.847, p＜0.001). In analysis of TCGA, mRNA differential expression of these genes revealed their corresponding upregulation or downregulation. Conclusion: BRAFV600E mutation or TCGA-validated IHC assay could be recommended as ancillary tests for classifying PTC.
Abstract
Background and Objectives: Ancillary tests such as BRAFV600E mutation or immunohistochemical (IHC) assays have been utilized as complements to morphological criteria in diagnosing subsets of papillary thyroid carcinoma (PTC). Utilizing results from analysis by The Cancer Genome Atlas (TCGA), we evaluated the diagnostic value and feasibility of these ancillary tests in diagnosing follicular variant PTC (FVPTC). Materials and Methods: Clinical data and tissue samples were analyzed from 370 PTC patients, who had undergone thyroidectomy between December 2003 and July 2014. PTC was limited to conventional PTC (CVPTC), tall cell variant PTC (TCPTC), and FVPTC. Using multivariate analyses, FVPTC cases were compared to CVPTC and TCPTC cases. Surgical specimens were pyrosequenced for BRAFV600E mutation or stained for IHC markers such as CD56, galectin-3, cytokeratin 19 (CK19), or CD31. For the validation, a comprehensive analysis was performed for BRAFV600E mutation and quantitative mRNA expressional difference in TCGA. Results: Demographic differences were not observed between 159 CVPTC, 103 TCPTC, and 108 FVPTC cases. BRAFV600E mutation predominated in CVPTC＋TCPTC group, but not in FVPTC group (78.4% vs. 18.7%, p＜0.001), as suggested by TCGA (57.4% vs. 12.1%, p＜0.0001). IHC markers significantly distinguished FVPTC cases from CVPTC＋TCPTC cases. CD56 exhibited more intense staining in FVPTC cases (21.1% vs. 72.0%, p＜0.001). Galectin-3 and CK19 yielded limited values. CD31 correlated with lymphovascular invasion (r=0.847, p＜0.001). In analysis of TCGA, mRNA differential expression of these genes revealed their corresponding upregulation or downregulation. Conclusion: BRAFV600E mutation or TCGA-validated IHC assay could be recommended as ancillary tests for classifying PTC.
참고문헌 (29)
- Ahn HS, "Korea's thyroid-cancer "epidemic"--screening and overdiagnosis", N Engl J Med, 371(19), pp.1765~1767 (2014)
- LiVolsi VA, "Papillary thyroid carcinoma: an update", Mod Pathol, 24(Suppl 2), pp.S1~S9 (2011)
- Schneider DF, "New developments in the diagnosis and treatment of thyroid cancer", CA Cancer J Clin, 63(6), pp.374~394 (2013)
- Salajegheh A, "Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists", Postgrad Med J, 84(988), pp.78~82 (2008)
- Chetty R, "Follicular patterned lesions of the thyroid gland: a practical algorithmic approach", J Clin Pathol, 64(9), pp.737~741 (2011)
- Elsheikh TM, "Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma", Am J Clin Pathol, 130(5), pp.736~744 (2008)
- Lloyd RV, "Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma", Am J Surg Pathol, 28(10), pp.1336~1340 (2004)
- Xing M, "Progress in molecular-based management of differentiated thyroid cancer", Lancet, 381(9871), pp.1058~1069 (2013)
- Ritterhouse LL, "BRAF V600E mutation-specific antibody: A review", Semin Diagn Pathol, 32(5), pp.400~408 (2015)
- Cheng S, "A highthroughput proteomic approach provides distinct signatures for thyroid cancer behavior", Clin Cancer Res, 17(8), pp.2385~2394 (2011)
- Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30(2), pp.216~222 (2006)
- Capper D, "Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody", Acta Neuropathol, 122(1), pp.11~19 (2011)
- Wiseman SM, "Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis", Ann Surg Oncol, 15(10), pp.2811~2826 (2008)
- Zhao M, "Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis", Oncol Lett, 11(1), pp.51~58 (2016)
- Serra S, "Controversies in thyroid pathology: the diagnosis of follicular neoplasms", Endocr Pathol, 19(3), pp.156~165 (2008)
- Fadda G, "Immunohistochemical diagnosis of thyroid tumors", Surg Pathol Clin, 7(4), pp.491~500 (2014)
- El Demellawy D, "Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid", Diagn Pathol, 3, pp.5~ (2008)
- Nechifor-Boila A, "Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56", Pathol Res Pract, 209(9), pp.585~592 (2013)
- Dunderovic D, "Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature", Diagn Pathol, 10, pp.196~ (2015)
- Alshenawy HA, "Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions", Pathol Oncol Res, 20(4), pp.819~828 (2014)
- Saleh HA, "Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules", Diagn Pathol, 5, pp.9~ (2010)
- Barut F, "Universal markers of thyroid malignancies:galectin-3, HBME-1, and cytokeratin-19", Endocr Pathol, 21(2), pp.80~89 (2010)
- Sethi K, "Biomarkers for the diagnosis of thyroid cancer", J Exp Ther Oncol, 8(4), pp.341~352 (2010)
- Isic Dencic T, "Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior", Med Oncol, 30(1), pp.362~ (2013)
- 이상혁, "Relationships between Lymph Node Metastasis and Expression of CD31, D2-40, and Vascular Endothelial Growth Factors A and C in Papillary Thyroid Cancer", Clinical and Experimental Otorhinolaryngology, 5(3), pp.150~155 (2012), 대한이비인후과학회[DOI]
- Asa SL, "Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist?", Thyroid, 25(1), pp.1~2 (2015)
- Cancer Genome Atlas Research Network, "Integrated genomic characterization of papillary thyroid carcinoma", Cell, 159(3), pp.676~690 (2014)
- Giordano TJ, "Follicular cell thyroid neoplasia: insights from genomics and The Cancer Genome Atlas research network", Curr Opin Oncol, 28(1), pp.1~4 (2016)
- Nikiforov YE, "Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors", JAMA Oncol, 2(8), pp.1023~1029 (2016)